Here's Why You Should Invest in Adverum (ADVM) Stock Now

Adverum Biotechnologies (ADVM) is developing single-administration gene therapies for highly prevalent ocular diseases, leveraging the potential of its proprietary intravitreal (IVT) platform. Its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), is being developed as a one-time IVT injection for patients with neovascular or wet age-related macular degeneration (wet AMD), a leading cause of blindness in patients over 65 years of age. In 2023, it made great progress in the development of Ixo-v ...